CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that a study on results from the Zemiva (iodofiltic acid I 123 or BMIPP) Phase 2b clinical trial has been accepted as an oral, late breaking presentation at the upcoming annual meeting of the American Society of Nuclear Cardiology (ASNC). The performance characteristics of Zemiva (BMIPP) SPECT imaging for detecting/ruling out Acute Coronary Syndrome (ACS) were investigated in a Phase 2b multicenter trial of 105 patients enrolled at eight study sites. Zemiva images from the trial were analyzed using the company’s validated reference database of normal images. The Zemiva Normals reference database, in conjunction with a quantitive program, assesses the performance of Zemiva in detecting and ruling out ACS.
